Residual immune dysregulation in human immunodeficiency virus infection: implications for hypersensitivity

Indry Agatha Rihi Pake; Anak Agung Made Widiasa; Ketut Suryana

doi:10.18203/2349-3933.ijam20250722

Authors

Indry Agatha Rihi Pake Department of Internal Medicine, Wangaya General Hospital, Denpasar, Bali, Indonesia
Anak Agung Made Widiasa Mahasaraswati University of Indonesia/Wangaya Regional General Hospital, Denpasar, Bali, Indonesia https://orcid.org/0000-0003-4465-1705
Ketut Suryana Department of Internal Medicine, Merpati Clinic, HIV Unit and Clinical Immunology Allergy, Wangaya General Hospital, Denpasar, Bali, Indonesia

DOI:

https://doi.org/10.18203/2349-3933.ijam20250722

Keywords:

HIV, Immune dysregulation, Hypersensitivity, Allergy, Antiretroviral therapy

Abstract

Residual immune dysregulation persists in people living with human immunodeficiency virus (PLWHIV) despite antiretroviral therapy (ART), characterized by chronic immune activation and imbalances in immune responses that increase the risk of allergic conditions such as drug hypersensitivity, atopic dermatitis (AD), and asthma. This literature review explores the mechanisms underlying immune dysregulation in PLWHIV and its implications for hypersensitivity reactions. HIV infection shifts the immune response from Th1 to Th2, increasing cytokine production, particularly IL-4 and IL-13, and elevating IgE levels, contributing to allergic reactions. Drug hypersensitivity, especially to nevirapine and abacavir, occurs more frequently in PLWHIV, with a higher risk of severe conditions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). The management of allergies in PLWHIV remains challenging due to persistent immune dysregulation, limited therapeutic options, and the lack of specific clinical guidelines. Understanding these immunological changes is crucial for developing better strategies for allergy prevention and management in this population.

Metrics

Metrics Loading ...

References

Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51-83. DOI: https://doi.org/10.1016/B978-0-12-407707-2.00002-3

McHugh RS, Shevach EM. The role of suppressor T cells in regulation of immune responses. J Allergy Clin Immunol. 2002;110(5):693-702. DOI: https://doi.org/10.1067/mai.2002.129339

Yunihastuti E, Widhani A, Karjadi TH. Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. Asia Pac Allergy. 2014;4(1):54-67. DOI: https://doi.org/10.5415/apallergy.2014.4.1.54

Scharping NE, Rivadeneira DB, Menk AV, Vignali PDA, Ford BR, Rittenhouse NL, et al. Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion. Nat Immunol. 2021;22(2):205-15. DOI: https://doi.org/10.1038/s41590-020-00834-9

Mu W, Patankar V, Kitchen S, Zhen A. Examining Chronic Inflammation, Immune Metabolism, and T Cell Dysfunction in HIV Infection. Viruses. 2024;16(2):219. DOI: https://doi.org/10.3390/v16020219

Rodriguez NR, Fortune T, Hegde E, Weinstein MP, Keane AM, Mangold JF, et al. Oxidative phosphorylation in HIV-1 infection: impacts on cellular metabolism and immune function. Front Immunol. 2024;15:1360342. DOI: https://doi.org/10.3389/fimmu.2024.1360342

Yu YR, Imrichova H, Wang H, Chao T, Xiao Z, Gao M, et al. Disturbed mitochondrial dynamics in CD8+ TILs reinforce T cell exhaustion. Nat Immunol. 2020;21(12):1540-51. DOI: https://doi.org/10.1038/s41590-020-0793-3

Temesgen Z, Beri G. HIV and drug allergy. Immunol Allergy Clin North Am. 2004;24(3):521-31. DOI: https://doi.org/10.1016/j.iac.2004.03.006

Coopman SA, Johnson RA, Platt R, Stern RS. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328(23):1670-4. DOI: https://doi.org/10.1056/NEJM199306103282304

Cai CW, Sereti I. Residual Immune Dysfunction Under Antiretroviral Therapy. Semin Immunol. 2021;51:101471. DOI: https://doi.org/10.1016/j.smim.2021.101471

Klatt NR, Silvestri G, Hirsch V. Nonpathogenic Simian Immunodeficiency Virus Infections. Cold Spring Harb Perspect Med. 2012;2(1):a007153. DOI: https://doi.org/10.1101/cshperspect.a007153

Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. J Infect Dis. 2011;203(6):780-90. DOI: https://doi.org/10.1093/infdis/jiq118

Bansal A, Sterrett S, Erdmann N, Westfall AO, Dionne-Odom J, Overton ET, et al. Normal T-cell activation in elite controllers with preserved CD4+ T-cell counts. AIDS. 2015;29(17):2245. DOI: https://doi.org/10.1097/QAD.0000000000000860

Krishnan S, Wilson EMP, Sheikh V, Rupert A, Mendoza D, Yang J, et al. Evidence for Innate Immune System Activation in HIV Type 1–Infected Elite Controllers. J Infect Dis. 2014;209(6):931-9. DOI: https://doi.org/10.1093/infdis/jit581

Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, et al. Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in the Absence of Viral Suppression. Immunity. 2016;44(2):391-405. DOI: https://doi.org/10.1016/j.immuni.2016.01.006

Krämer B, Goeser F, Lutz P, Glässner A, Boesecke C, Schwarze-Zander C, et al. Compartment-specific distribution of human intestinal innate lymphoid cells is altered in HIV patients under effective therapy. PLOS Pathog. 2017;13(5):e1006373. DOI: https://doi.org/10.1371/journal.ppat.1006373

Cosgrove C, Ussher JE, Rauch A, Gärtner K, Kurioka A, Hühn MH, et al. Early and non-reversible decrease of CD161++/MAIT cells in HIV infection. Blood. 2013;121(6):951-61. DOI: https://doi.org/10.1182/blood-2012-06-436436

Minhajat R, Djaharuddin I, Halim R, Benyamin AF, Bakri S. Drugs hypersensitivity reaction in patient with human immunodeficiency virus (HIV) Infection. J Allergy Ther. 2017;8:252. DOI: https://doi.org/10.4172/2155-6121.1000252

Becker Y. The changes in the T helper 1 (Th1) and T helper 2 (Th2) cytokine balance during HIV-1 infection are indicative of an allergic response to viral proteins that may be reversed by Th2 cytokine inhibitors and immune response modifiers-A review and hypothesis. Virus Genes. 2004;28:5-18. DOI: https://doi.org/10.1023/B:VIRU.0000012260.32578.72

Calabrese LH (1988) Autoimmune manifestations of human immunodeficiency virus (HIV) infection. Clin Lab Med. 1988;8:269-79. DOI: https://doi.org/10.1016/S0272-2712(18)30683-8

Fenwick C, Joo V, Jacquier P, Noto A, Banga R, Perreau M, Pantaleo G. T-cell exhaustion in HIV infection. Immunol. Rev. 2019;292:149-63. DOI: https://doi.org/10.1111/imr.12823

Yates KB, Tonnerre P, Martin GE, Gerdemann U, Al Abosy R, Comstock DE, et al. Epigenetic scars of CD8+ T cell exhaustion persist after cure of chronic infection in humans. Nat Immunol. 2021;22:1020-9. DOI: https://doi.org/10.1038/s41590-021-00979-1

Meyaard L, Otto SA, Keet IP. Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection. Blood. 1994;84:4262-8. DOI: https://doi.org/10.1182/blood.V84.12.4262.bloodjournal84124262

Adiningtyas V, Sigit Prakoeswa CR, Triyono EA. Cutaneous adverse drug reaction in Human Immunodeficiency virus patient associated with antiviral therapy: A retrospective study. Dermatol Reports. 2019;11(S1):8059. DOI: https://doi.org/10.4081/dr.2019.8059

Guevara PM, Chacón DDD, Orozco AM de, Salazar P, González G, Zambrano CMG, et al. Hypersensitivity to environmental allergens in HIV-infected patients: Is atopy more frequent? J Allergy Clin Immunol. 2005;115(2):S224. DOI: https://doi.org/10.1016/j.jaci.2004.12.904

Israël-Biet D, Labrousse F, Tourani JM, Sors H, Andrieu JM, Even P. Elevation of IgE in HIV-infected subjects: a marker of poor prognosis. J Allergy Clin Immunol. 1992;89(1 Pt 1):68-75. DOI: https://doi.org/10.1016/S0091-6749(05)80042-9

Clerici M, Sarin A, Henkart PA, Shearer GM. Apoptotic cell death and cytokine dysregulation in human immunodeficiency virus infection: pivotal factors in disease progression. Cell Death Differ. 1997;4(8):699-706. DOI: https://doi.org/10.1038/sj.cdd.4400314

Alawadhi A, Karibayeva D, Gottlieb AB. Dupilumab in HIV-positive patients: A case series report of 4 patients. JAAD Case Rep. 2020;6(12):1356-9. DOI: https://doi.org/10.1016/j.jdcr.2020.09.023

Brodska P, Panzner P, Sedlacek D, Terl M, Cetkovska P. Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection. Dermatol Ther. 2020;33(6):e14159. DOI: https://doi.org/10.1111/dth.14159

Hoosen K, Mosam A, Dlova NC, Grayson W. An Update on Adverse Cutaneous Drug Reactions in HIV/AIDS. Dermatopathol Basel Switz. 2019;6(2):111-25. DOI: https://doi.org/10.1159/000496389

Davis CM, Shearer WT. Diagnosis and management of HIV drug hypersensitivity. J Allergy Clin Immunol. 2008;121(4):826-32. DOI: https://doi.org/10.1016/j.jaci.2007.10.021

Siberry GK, Paul ME, Shearer WT. HIV infection and allergic disease. In: Middleton’s allergy: Principles and practice. Philadelphia: Elsevier. 2020;1168-80.